Streetbeat News

APRE

Aprea Therapeutics, Inc.

https://atrinpharma.com

Industry

Biotechnology

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Open

3.28

Mkt cap

18M

Volume

16K

High

3.45

P/E Ratio

-1.16

52-wk high

8.85

Low

3.06

Div yield

N/A

52-wk low

2.15

Aprea Therapeutics (APRE) has formed a hammer chart pattern, suggesting support and potential trend reversal. Upward earnings estimate revisions further support a positive outlook for the stock.

Portfolio Pulse from

November 13, 2024 | 4:00 pm

Aprea Therapeutics, Inc. (APRE) reported a Q3 loss of $0.64 per share, which was better than the Zacks Consensus Estimate of a $0.75 loss. This is an improvement from the $0.86 loss per share reported a year ago.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics, maintaining a $20 price target. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 9:39 am

Aprea Therapeutics presented preliminary findings on its oral WEE1 inhibitor, APR-1051, at an international conference. The Phase 1 trial shows APR-1051 is safe and well-tolerated with no hematologic toxicity. The study is ongoing with active enrollment in the U.S.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:35 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 2:34 pm

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:50 pm

Aprea Therapeutics (NASDAQ:APRE) reported Q2 earnings per share (EPS) of $(0.58), beating the analyst estimate of $(0.64) by 9.38%. The company also reported sales of $561.57K, surpassing the $50.00K estimate by 1,020%. This represents a significant improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:41 pm

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:34 pm

Aprea Therapeutics will host a virtual Key Opinion Leader (KOL) event on June 24, 2024, to discuss APR-1051, a selective oral WEE1 inhibitor. The event will feature medicinal chemistry expert Joseph Vacca and University of Pennsylvania's Eric J. Brown, who will discuss preclinical findings.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.